VAERS Explorer
Back to explore

Report #2834409

Received Feb 19, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Female
Age
Age unknown
State
—
Recovered
Unknown
Vaccinated
—
Onset
—
Days to onset
—
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
VARZOSZOSTER (SHINGRIX)GLAXOSMITHKLINE BIOLOGICALS1——

Symptoms (1)

Pruritus

Symptom narrative

itching; This non-serious case was reported by a consumer via patient support programs and described the occurrence of pruritus in a female patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced pruritus (Verbatim: itching). The outcome of the pruritus was not reported. It was unknown if the reporter considered the pruritus to be related to Shingrix. It was unknown if the company considered the pruritus to be related to Shingrix. Linked case(s) involving the same patient: US2025007560 Additional Information: GSK Receipt Date: 21-JAN-2025 The patient is the reporter. Patient experienced itching after her first dose of Shingrix. For the tolerance of 2nd dose refer US2025007560; Sender's Comments: US-GSK-US2025007560:2nd dose